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Abstract
The Liver Imaging-Reporting and Data System (LI-RADS or LR) is a classification system for reading and reporting 
imaging studies in patients with high risk for hepatocellular carcinoma (HCC). One of its main goals is to improve 
communication between specialties, especially radiologists, hepatologists, surgeons, and pathologists. LI-RADS de-
fines imaging features of the lesions and stratifies the risk of HCC into categories. It is the most comprehensive and 
highly specific system; however, its seeming complexity prevents many radiologists from using it in everyday practice. 
This article is a detailed review of the latest version of LI-RADS (v. 2017), which should be helpful for radiologists 
who are not very familiar with the system and its latest update.
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Introduction
The Liver Imaging-Reporting and Data System (LI-RADS 
or LR) is a system created to standardise reading and re-
porting of CT and MR studies for hepatocellular carcino-
ma (HCC). The system has been designed by a committee 
consisting of diagnostic and interventional radiologists, 
surgeons, hepatologists, and pathologists and is supported 
by the American College of Radiology (ACR) [1]. 
There have been many attempts [2] to standardise di-
agnosis and management of HCC over the last 15 years 
(Table 1). LI-RADS was designed to add more shades of 
grey to existing systems and to create a comprehensive 
system that can be used by any radiologist. The result 
should give the highest possible specificity for HCC be-
cause the LR-5 category is supposed to be a guarantee that 
a lesion is HCC and intervention can be done based solely 
on the imaging report. The studies published so far have 
reported very good sensitivity and specificity of LI-RADS 
for HCC diagnosis [3-5]. The CT/MRI LI-RADS v2017 
classification applies to multiphase CT and MR exami-
nations only. The system can guide a radiologist through 
the reading and reporting process. The result should be 
uniform for any radiologist in the world and easily un-
derstood by any physician involved in HCC diagnosis and 
treatment.
LI-RADS does not offer definite management rec-
ommendations but it does give some suggestions. Above 
all, it is supposed to detect probable or definite HCC and 
leave the management options open.
Table 1. Popular guidelines for imaging diagnosis of hepatocellular carci-
noma (HCC)
AASLD and EASL – for patients at risk for HCC being in an ultrasound 
surveillance program. Meant to be used by radiologists with expertise 
in liver imaging.
OPTN – used for eligibility for liver transplantation based on CT  
and MRI criteria, meant to be used by radiologists in liver 
transplantation centres.
LI-RADS – for all patients at risk for HCC, meant to be used by  
all radiologists.
ESGAR – liver MR imaging guidelines including HCC diagnosis,  
but without management recommendations.
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There are three LI-RADS algorithms, and they all ap-
ply to high-risk patients:
1. Ultrasound LI-RADS uses unenhanced ultrasound for 
screening and surveillance for HCC in high-risk patients.
2. CEUS LI-RADS uses contrast-enhanced ultrasound 
(CEUS) for diagnosis of HCC.
3. CT/MRI LI-RADS uses multiphase CT and MR ex-
aminations for diagnosis of HCC and for treatment response 
assessment. For the purpose of this article the CT/MRI LI-
RADS® v2017 algorithm will be referred to as LI-RADS.
The first version of LI-RADS was released in 2011, and 
since then there have been changes in every version, in-
cluding the most recent one from 2017 (Figure 1).
Many changes were introduced in the 2017 version 
of LI-RADS including a new algorithm (Treatment Re-
sponse Assessment), new and revised categories (LR-NC 
and LR-TIV), new threshold growth definition, modifi-
cations of ancillary features, and clarification on how to 
use many other features of the system. The next update 
is expected to be released in 2020 or 2021, and it should 
include a Path category for pathologically proven HCCs.
The aim of this article is to show how to use CT/MRI 
LI-RADS in everyday practice.
LI-RADS can be applied to CT or MR examinations 
in patients with high risk of HCC. The risk factors are: 
cirrhosis OR chronic HBV infection OR diagnosed HCC 
now or in the past.
The following patients are excluded from LI-RADS 
classification: 
•	 no risk factors,
•	 < 18 years old,
•	 with cirrhosis due to congenital hepatic fibrosis and 
vascular disorders such as hereditary haemorrhagic 
telangiectasia, Budd-Chiari syndrome, chronic portal 
vein occlusion, cardiac congestion, or diffuse nodular 
regenerative hyperplasia. 
The rationale behind this is that in paediatric patients 
or in patients with the above conditions there can be many 
false positives and the positive predictive value may be too 
low.
Technique
LI-RADS v2017 does not suggest any particular contrast 
agent; however, there are technical recommendations 
on modalities and contrast media used in the imaging 
studies. Arterial phase, portal venous phase, and delayed 
venous phase (or transitional phase with gadoxetate diso-
dium [Gd-EOB-DTPA]) are required. Pre-contrast phase 
is suggested. Late arterial phase is strongly preferred over 
early arterial phase because some HCCs hyperenhance 
only in the late arterial phase [6,7]. Post-contrast phases 
with liver appearances are listed in Table 2.
Reporting
The term “observation” rather than “lesion” or “nodule” 
is preferred because not all suspicious findings are actual 
Figure 1. LI-RADS CT/MRI algorithm (https://www.acr.org/Quality-Safety/Resources/LIRADS/LIRADS-v2017)
Size 
No arterial hyperenhancement Arterial hyperenhancement
< 20 mm ≥ 20 mm < 10 mm 10-19 mm ≥ 20 mm
How many of these features: 
•	 washout None LR-3 LR-3 LR-3 LR-3 LR-4
•	 capsule One LR-3 LR-4 LR-4 LR-4/LR-5 LR-5
•	 threshold growth ≥ 2 LR-4 LR-4 LR-4 LR-5 LR-5
Table 2. Liver appearance in specific phases after contrast injection
Phase Time after contrast injection Appearance of liver parenchyma and vessels
Early arterial phase 15-25 s Portal vein is not enhanced.
Late arterial phase 30-40 s Portal vein is enhanced, hepatic veins are not yet enhanced.
Portal venous phase (PVP) 70-80 s Portal veins and liver parenchyma are fully enhanced and 
hepatic veins already get antegrade flow.
Delayed phase – obtained with extracellular 
contrast agents or gadobenate dimeglumine  
(Gd-BOPTA)
2-5 min Portal and hepatic veins as well as (usually) liver parenchyma 
enhancing less than in PVP.
Transitional phase – obtained with 
gadoxetate disodium (Gd-EOB-DTPA)
2-5 min Similar enhancement of liver vessels and parenchyma  
(overlap of extracellular and intracellular effect  
of Gd-EOB-DTPA).
Hepatobiliary phase 20 min after Gd-EOB-DTPA;  
1-3 hours after Gd-BOPTA
Contrast is visible in biliary tree and liver vessels  
are hypointense compared to liver parenchyma.
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lesions in follow-up. This is supposed to exclude pseudo- 
lesions.
According to the guidelines, LR-1 entities that are defi-
nitely benign (Figures 2A-B) and LR-2 that causes no diag-
nostic confusion have no clinical relevance and therefore 
should be reported in aggregate unless they were suspi-
cious in the previous examinations (then a rationale for 
this downgrade should be provided). Examples of LR-1 
and LR-2 observations are listed in Table 3 and Table 4. 
All LR-3, LR-4, LR-5, LR-5V, and LR-M observations must 
be reported.
Lesions that have features of FNH or adenoma typi-
cally should be classified as LR-3 because the classification 
concerns patients with high risk of HCC.
Observations categorised as LR-3 have a similar prob-
ability of being benign and being HCC. They should be 
reported, and the clinician’s choice whether to proceed 
with further investigation, e.g. additional imaging or 
shorter follow-up, is clinically justified. 
LR-4 observation is not 100% HCC, but this diagnosis 
is very likely, so the patient should probably have a biopsy, 
shorter follow-up (for example, 2-3 months), or correla-
tion with laboratory results – all depending on practice 
and guidelines at a local institution.
LR-TIV – tumour in vein – should be reported with 
the most probable aetiology:
If tumour in vein is a continuation of an LR-5 lesion, 
then use the term “definitely due to HCC”. If it is associat-
ed with an LR-4 lesion or infiltrative mass, then use term 
“probably due to HCC”. 
The lesions that are associated with targetoid mass 
should be reported as “may be due to non-HCC malig-
nancy”. All other cases should be reported as “aetiology 
uncertain”. LR-M means a non-HCC malignancy seen as 
any targetoid mass or as a non-targetoid mass with at least 
one of the following features:
•	 infiltrative appearance,
•	 pronounced restriction of diffusion,
•	 necrosis or severe ischaemia,
•	 other features suggesting non-HCC malignancy (should 
be specified in the report).
The LR-M lesion should not meet LR-5 or LR-TIV 
criteria.
Targetoid or target-like appearance presents as con-
centric alignment of the lesion’s components; for example, 
rim of arterial enhancement or washout, delayed central 
Figure 2. LI-RADS 1 observations. A) T2-weighted image – simple cyst 
(white arrow). B) Contrast enhanced computed tomography – haeman-
gioma (black arrow)
A
B
Table 3. Examples of LI-RADS 1 observations
LI-RADS 1 entities (examples)
Definitely:
Cyst
Haemangioma
Vascular anomaly
Perfusion alteration (e.g. arterioportal shunt)
Hepatic fat deposition or sparing
Hypertrophic pseudomass
Confluent fibrosis or focal scar
Observation that spontaneously disappears at follow-up
Table 4. Examples of LI-RADS 2 observations
LI-RADS 2 entities (examples)
Probably:
Cyst
Haemangioma
Vascular anomaly
Perfusion alteration (e.g. arterioportal shunt)
Hepatic fat deposition or sparing
Hypertrophic pseudomass
Confluent fibrosis or focal scar
Distinctive nodule without malignant features is a solid lesion < 2 cm, 
which does not have any major or ancillary features of malignancy.
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erally, a category with lower level of certainty should be 
reported. 
STEP 1 – first apply the algorithm
In the first step the following categories should be excluded:
•	 LR-NC – observation cannot be categorised due to poor 
quality or lack of images,
•	 LR-1 – definitely benign,
•	 LR-2 – probably benign,
•	 LR-TIV – tumour in vein,
•	 LR-M – probably or definitely malignant but not typical 
HCC.
If none of the abovementioned categories is appropri-
ate, then apply the CT/MRI LI-RADS table (LIRADS-ta-
ble.jpg). The table includes the following categories:
•	 LR-3 – intermediate probability of malignancy,
•	 LR-4 – probably HCC,
•	 LR-5 – definitely HCC.
If unsure whether the feature is present, do not report it.
Categories
An observation classified as LI-RADS 1 is definitely be-
nign based on benign features or disappearance in fol-
low-up examination (examples in Table 3).
LI-RADS 2 category observations are probably benign 
since the features are suggestive but not diagnostic for be-
nign lesions (examples in Table 4).
LI-RADS 3 category is for observations that do not 
meet criteria for other LI-RADS categories and have sim-
ilar probability of being benign and malignant. 
LI-RADS 4 category contains observations that are 
probably HCCs but imaging features are not diagnostic. 
LI-RADS 5 category contains observations that are 
100% proven HCCs based on their imaging features.
LI-RADS TIV category is for tumours that definitely 
invade a vein presenting as enhancing tissue expanding 
the vein (Figure 4). There are additional features that sug-
gest tumour in vein and should prompt a more detailed 
examination of the vein in the search for enhancing soft 
tissue. The features include: occluded vein with ill-de-
fined walls or restricted diffusion, occluded or obscured 
vein adjacent to malignant parenchymal mass, and het-
erogeneous vein enhancement that is not caused by ar-
tefact.
LI-RADS 5G is for observations that have grown by 
> 50% within six months, which is an equivalent to OPTN 
5A-g category.
LI-RADS 5US is for observations that present washout 
AND are visible on ultrasound (typically for patients in 
surveillance program, as in AASLD criteria).
LI-RADS M category is for malignant tumours other 
than HCC.
Figure 3. Ancillary features of LI-RADS classification
Ancillary features that may favor malignancy 
Ancillary features that may favor benignity
LR-1 LR-2 LR-3 LR-4 LR-5
Tie-breaking rules 
LR-1 or LR-2 = LR-2 
LR-2 or LR-3 = LR-3 
LR-3 or LR-4 = LR-3 
LR-4 or LR-5 = LR-4 
LR-3 or LR-M = LR-3 
LR-4 or LR-M = LR-M 
LR-5 or LR-M = LR-M
Table 5. Tie-breaking rules of LI-RADS classification
Figure 4. Contrast enhanced computed tomography. Tumour tissue expand-
ing right branch of portal vein (arrow)
enhancement or concentric pattern on diffusion weighted 
images (DWI), or hepatobiliary phase.
Any relevant change of the observation since prior 
studies should be reported.
Pathologically proven lesions should not have LI-RADS 
category assigned. The only exception is a benign lesion 
of hepatocellular origin, e.g. regenerative or dysplastic 
nodule, because it will help in future monitoring of the 
observation.
Categorisation
First apply major features (Figure 1). If uncertain about 
the category, apply ancillary features (Figure 3) to upgrade 
(up to – but not above – LR-4) or downgrade category. 
If still unsure, apply tie-breaking rules (Table 5). Gen-
 CT/MRI LI-RADS v2017 – review of the guidelines
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LI-RADS TR stands for loco-regionally treated tu-
mour, e.g. transarterial chemoembolisation (TACE) or 
ablation. 
Major features
Major features are used for categorisation of LR-3, LR-4, 
and LR-5 observations. They need to be unequivocally 
present to be considered in this classification. 
Arterial phase hyperenhancement
HCCs can be roughly divided into early and progressed 
stages. Early HCCs are well differentiated and have min-
imal neo-arterialisation, which leads to poor or no en-
hancement in the arterial phase. Late (progressed) HCCs 
are poorly differentiated, have well developed new arterial 
vessels, and they hyperenhance in the arterial phase. 
Arterial phase hyperenhancement is a major LI-RADS 
feature and describes observations that have higher atten-
uation than the rest of the liver (Figure 5). It applies to 
both whole and parts of observations. It should be as-
sessed in the late arterial phase when arteries and portal 
veins are enhanced but before antegrade flow into hepatic 
veins. The rationale behind this is higher sensitivity of the 
late comparing to early arterial phase [7]. Arterial phase 
hyperenhancement is the essential feature for a lesion to 
be categorised as LR-5. Rim hyperenhancement in arterial 
phase is considered targetoid in appearance and is a fea-
ture of LR-M category.
Arterial phase hypo- or isoenhancement includes 
observations that enhance less or the same as the rest of 
the liver. This applies to both whole and parts of observa-
tions. It does not apply to non-enhancing observations. 
Observations that show hypo- or isoenhancement should 
be categorised as LR-3 or LR-4 (depending on other 
features, e.g. diameter). Subtraction or region of inter-
est (ROI) measurements can be used if the observation 
is hyperintense on pre-contrast T1-weighted images (Fig-
ures 6A-B). 
Washout appearance
It is defined as decreased enhancement of the observation 
or part of it, compared to the liver parenchyma surround-
ing the observation (Figure 7). It must be visible in portal 
venous phase or delayed venous phase. For Gd-EOB-
DTPA it can be reported in portal venous phase only. It 
should not be mistaken for peripheral “washout”, which is 
a feature of LR-M category. 
Any enhancing observation can have washout appear-
ance reported – arterial phase hyperenhancement is not 
required. 
Washout appearance is assessed visually, but radiolo-
gists may use region of interest (ROI) measurements and 
subtraction at their discretion. 
Figure 5. Contrast enhanced magnetic resonance imaging. Observation 
presenting arterial hyperenhancement (arrow)
Figure 6. A) T1-weighted image with hyperintense observation. B) Signal 
intensity measurement with region of interest (ROI) shows enhancement 
of the lesion
B
A
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Capsule appearance
The term “capsule appearance” is preferred over “capsule” 
because the observation can sometimes represent pseu-
docapsule rather than true capsule. Capsule appearance 
means a rim of hyperenhancement (Figure 7) in portal, 
delayed, or transitional phase, which is unequivocally 
thicker than fibrotic tissue around background nodules.
It should not be mistaken for corona enhancement or 
nonenhancing capsule, which are ancillary features fa-
vouring, respectively, malignancy and particularly HCC.
Size
The observation’s size should be measured as the largest 
diameter including the capsule. The measurement should 
be made on the sequence where the observation’s border 
is distinct enough. Arterial phase and DWI should not be 
used for measurement if other sequences show the obser-
vation’s border. Perilesional enhancement in arterial phase 
and anatomic distortion on DWI make these sequences 
less reliable in terms of size measurement. 
Threshold growth
It is defined as the increase of the diameter of the observa-
tion by at least 5 mm and one of the following:
•	 ≥ 50% increase in size within ≤ 6 months,
•	 ≥ 100% increase in size within > 6 months.
A new (not seen on CT or MRI in the previous two 
years) observation ≥ 10 mm also represents threshold 
growth (Figures 8A-B). The diameter should be assessed 
on images in the same plane and, if possible, acquired in 
the same phase / sequence with margins of the observa-
tion well defined.
Step 2 – if not sure, apply ancillary features
Application of ancillary features may be used at the ra-
diologist’s discretion. Ancillary features can be used to 
downgrade or upgrade the category. However, they cannot 
be used to upgrade the category to LR-5. The absence of 
ancillary features cannot be used as a reason to upgrade 
or downgrade the category.
Ancillary features favouring malignancy  
(not necessary HCC)
Ultrasound visibility as discrete nodule
It refers to an observation detected on CT or MRI that is visi-
ble as a discrete nodule or a mass on unenhanced ultrasound.
Subthreshold growth
It is defined as a growth lower than the threshold (de-
scribed above).
Figure 7. Washout and capsule appearance (arrow) – delayed venous phase 
magnetic resonance imaging
Figure 8. Contrast enhanced computed tomography (CT), arterial phase. 
A) No suspicious lesions on first CT. B) Several hyperenhancing observations 
on CT performed 7 months later, including one observation 12 mm in diam-
eter in left lobe (white arrow)
B
A
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Corona enhancement
A zone of hyperenhancement around the observation vis-
ible in late arterial and early portal phases is called coro-
na enhancement. It applies to masses that hyperenhance 
diffusely in the early arterial phase. Enhancement of the 
lesion later fades away while the perilesional rim of en-
hancement increases. It is a feature of late HCC and rep-
resents drainage of contrast from tumour to surrounding 
tissue.
Fat sparing in solid mass
It applies to observations that have less fat than the sur-
rounding fatty liver or non-fatty fragment of observation 
in a steatotic nodule. It should be differentiated from he-
patic fat sparing; in lesional fat sparing the observation is 
a mass that enhances differently than the rest of the liver.
Restricted diffusion
High signal on DWI (with moderate and high b values, 
e.g. > 400 s/mm2) and/or low ADC map signal represent 
restricted diffusion, which is an ancillary feature favour-
ing malignancy (Figures 9A-B). Intra-lesional fat, cirrho-
sis, and relative lack of increased cellularity (compared to 
metastases) may decrease its sensitivity.
Mild–moderate T2 hyperintensity
It is defined as mildly to moderately higher signal of the 
observation compared to the rest of the liver (Figure 10). 
Infiltrative HCCs are often hyperintense on T2-weighted 
images, sometimes without arterial hyperenhancement. 
If unsure, do not report as mild-moderate T2 hyperin-
tensity. 
Iron sparing in solid mass
It describes an observation with lower iron content than 
iron-overloaded liver parenchyma or in a fragment of 
otherwise siderotic lesion. On T2-weighted MR images 
it presents as increased intensity of the lesion relative to 
hypointense, iron-overloaded liver parenchyma. MRI is 
more sensitive than CT for the detection of iron overload 
nodules.
Transitional phase hypointensity
Transitional phase occurs after delayed venous phase 
but before hepatobiliary phase and applies only to Gd-
EOB-DTPA. In this phase both intra- and extracellular 
components of the Gd-EOB-DTPA effect contribute to 
contrast enhancement. Hypoenhancement in this phase 
is an ancillary feature favouring malignancy. Transitional 
phase is typically acquired 2-5 minutes after injection of 
gadoxetate.
Figure 9. Observation presenting restriction of diffusion – high signal on 
diffusion weighted image (A) (arrow) with low signal on ADC map (B) (ar-
row)
A
B
Figure 10. Moderately hyperintense observation on T2-weighted image
Hepatobiliary phase hypoenhancement
It is defined as lower attenuation than the rest of the liver 
in the hepatobiliary phase (Figure 11). It should not be 
mistaken for washout, which is a major feature. Washout 
should be assessed only in the extracellular phase (por-
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tal venous or delayed phase), before hepatobiliary con-
trast media uptake by hepatocytes. Hepatobiliary phase 
hypointensity is characteristic but not specific for HCC; 
therefore, it was defined as an ancillary feature. 
Figure 11. Hypointense observation (arrow) on magnetic resonance imag-
ing in hepatobiliary phase
A
B
Figure 12. Signal intensity drop in out-of-phase magnetic resonance imag-
ing image (A) (black arrow) compared to in-phase image (B) (white arrow)
If unsure whether the observation is hypo- or isoenhanc-
ing in the hepatobiliary phase, report it as isoenhancing. 
Ancillary features favouring HCC in particular
Nonenhancing “capsule”
It is defined as capsule appearance without its enhance-
ment. It is defined as a smooth border around the obser-
vation, different in signal from both observation and the 
rest of the liver. It does not qualify as capsule appearance, 
which presents as rim enhancement limited to portal ve-
nous and delayed phase.
Nodule-in-nodule appearance
It presents as a small nodule within a larger outer nod-
ule, and both nodules differ in appearance. It is one of 
the types of mosaic appearance (see below). The whole 
(larger) nodule should be measured, not the small nodule 
inside. 
Mosaic architecture
It applies to different appearances with random distribu-
tion in different areas (nodules, compartments) within 
the same observation. It is an ancillary feature favour-
ing malignancy, especially HCC. Examples include nod-
ule-in-nodule, multi-nodule-in-nodule, multi-compart-
ment-in-nodule, and septated solid mass. In patients with 
cirrhosis or other risk factors for HCC, most masses with 
mosaic architecture are HCCs. 
Fat in mass
It is defined as higher fat content than in the liver paren-
chyma. MRI is more sensitive and specific for fat detec-
tion. In-phase and out-of-phase images (Figure 12A-B) 
as well as sequences with fat saturation can be used. 
The most common form of intralesional fat is intracel-
lular lipids, and they can be detected by in- and out-of-
phase images, while frequency-selective fat saturation 
technique can be used to detect less common macro-
scopic fat.
It needs to be differentiated with hepatic fat deposition 
in background liver. Intra-lesional fat is favoured over hepat-
ic fat deposition if the observation is a mass or it enhances 
differently than the liver parenchyma in at least one phase.
Blood products in mass
It presents as blood products within or around the obser-
vation without a history of trauma or intervention. On 
CT blood products usually present with increased densi-
ty, but it applies mostly to early phases of haemorrhage. 
On MRI blood products typically show heterogeneous 
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hyperintensity on T1-weighted images and hypointensity 
on T2-weighted images. However, T1-hyperintensity can 
be also seen in the presence of fat, copper, or concentrat-
ed proteins. Also, blood degradation products often look 
different than fresh blood, with non-uniform appearance 
on both T1- and T2-weighted sequences.
MRI is more sensitive and specific for blood product 
detection than CT.
Ancillary features favouring benignity
Size stability ≥ 2 years
The observation is considered stable when there is no sig-
nificant change in size over a two-year period. This applies 
to patients who were not treated.
Size reduction
It is defined as a spontaneous decrease in observation di-
ameter that is not due to technique, artefact, measurement 
error, or resorption of blood products.
Parallels blood pool enhancement
Observation’s enhancement matching blood pool is 
a characteristic feature of haemangioma thus being an 
ancillary feature favouring benignity.
Undistorted vessels
Undistorted vessels are defined as arteries or veins pass-
ing through the observation without displacement or any 
other alteration.
Iron in mass, more than liver
It presents as increased iron content in the observation 
compared to the remaining liver parenchyma. It can be 
difficult to estimate on CT. MRI is more sensitive than 
CT in terms of iron detection, and it shows low signal 
intensity on T2-weighted images. 
Marked T2 hyperintensity
High signal on T2-weighted images, similar to fluid in bile 
ducts or gallbladder, is a feature typical for haemangioma 
and thus favouring benignity.
Hepatobiliary phase isointensity
It is defined as identical or almost identical signal intensity 
of the observation and the surrounding liver parenchyma.
The ancillary features can only be applied after tak-
ing major features into consideration, and they allow for 
moving observation from lower categories up to LR-4. 
The LR-5 category needs to be confirmed by major fea-
tures. If the observation has ancillary features favouring 
both benignity and malignancy, then do not adjust the 
category.
An observation that, according to major features, 
belongs to LR-5 but has at least two ancillary benign fea-
tures (8) can be downgraded to lower categories (Figure 3).
STEP 3 – if still not sure, apply tie-breaking 
rules…
Tie-breaking rules can be used when major and ancillary 
features still do not give a certain answer. They can be 
applied as in Table 5, after going through major features 
algorithm and then using ancillary features. The general 
rule is that tie-breaking rules move observations to a cat-
egory with a lower degree of certainty.
Infiltrative appearance
Infiltrative appearance is a description of ill-defined ob-
servations, frequently extending over multiple segments. 
They often represent HCCs, while hepatocholangiocarci-
noma, intrahepatic cholangiocarcinoma, lymphoma, or 
metastases are less frequent. It is also difficult to distin-
guish between true malignancy and benign entities such 
as perfusion alteration or non-homogenous fat or iron 
deposition. Such benign entities should be categorised as 
LR-2. Vein invasion should be reported as LR-TIV and 
LR-5 lesions – according to major LI-RADS features. 
All other observations should be categorised as LR-M. 
There are features that suggest a malignant nature of the 
infiltrative appearance and they include tumour in vein, 
ill-defined veins, heterogeneity of the observation (with 
or without contrast), low T1 and moderately high T2 sig-
nal, restricted diffusion, multiple indistinct nodules, and 
generally distorted architecture of the parenchyma. 
Treatment response algorithm
In the new version of LI-RADS a detailed treatment re-
sponse assessment algorithm was introduced. The algo-
rithm should be applied in the first step of treatment re-
sponse evaluation.
First, it should be determined whether the technical fea-
tures of the images allow assessment of the treated lesion.
If the images are corrupt or missing, then the lesion 
should have the “LR-TR Nonevaluable” category assigned.
If the images are technically acceptable, then one of 
the following three categories should be used:
The LR-TR Nonviable category should be assigned for 
non-enhancing lesions (Figure 13) or presenting enhance-
ment pattern typical for the treatment.
The LR-TR Equivocal category is for lesions that do 
not show typical viable tumour pattern and their enhance-
ment is atypical for treated lesions.
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The LR-TR Viable category should be assigned for 
lesions with or adjacent to irregular tissue with: arterial 
hyperenhancement (Figure 14) OR washout OR enhance-
ment pattern resembling lesion before the treatment. 
In the second step viable tumour tissue diameter 
should be measured. The largest enhancing area should 
be measured along its longest dimension, but the meas-
urement cannot pass through the nonenhancing part of 
the observation.
If not sure about category choice, one should use LR-TR 
Equivocal, which is the category with lower certainty.
In the final check make sure the category choice is 
reasonable.
Management
AASLD and EASL have recommendations for lesions that 
are definitely HCCs (LR-5) but not for “indeterminate” 
nodules (LI-RADS-2, -3, and -4). LI-RADS does not give 
definite answers on management, but it does give some 
suggestions. 
Management options for LR-2, LR-3, or LR-4 observa-
tions may include continuation of standard surveillance, 
accelerated surveillance, or repeated exam with an alterna-
tive imaging method or biopsy. The decision between these 
options does not come directly from the LI-RADS catego-
ry because clinical data should be taken into consideration. 
Recommendation of biopsy should be based on multidisci-
plinary team discussion, not solely on imaging [1]. 
LR-1 and LR-2 observations should be under standard 
surveillance, which is ultrasound every six months. For 
LR-3 observations diagnostic imaging (CT or MR) should 
be repeated within 3-6 months or an alternative modality 
should be used. Observations that have higher risk of be-
ing malignant should be evaluated by a multidisciplinary 
team, which includes LR-TR-viable lesions.
Other classification systems
Some of the most popular guidelines for liver cancer have 
been issued by the American Association for the Study of 
Liver Diseases (AASLD) [9], the European Association for 
the Study of the Liver, and the European Organisation for 
Research and Treatment of Cancer (EASL-EORTC) [10].
AASLD and EASL criteria categorise nodules into one 
of three classes: HCC, indeterminate, or benign. LI-RADS 
with its five categories adds more granularity to HCC cat-
egorisation.
EASL and AASLD algorithms are very similar. Both 
algorithms are for cirrhotic patients who are under ul-
trasound surveillance. Ultrasound examinations are per-
formed every six months. For detected nodules < 1 cm 
ultrasound should be repeated every three months (AAS-
LD) or four months (EASL). For nodules > 1 cm both 
algorithms recommend dynamic MR or CT (EASL prefers 
both modalities for lesions 1-2 cm) [11]. 
In the United States there are also the Organ Procure-
ment and Transplantation Network (OPTN) criteria for 
patients with HCC, who are considered for liver trans-
plantation [12]. OPTN 0 class means incomplete/inade-
quate study, which is similar to LR-NC category of LI-
RADS. The classes 1-5 are also similar to LI-RADS, with 
OPTN 5 class meaning definitely HCC. OPTN class 5 is 
divided into subclasses: 5A: 1-2 cm lesion (hyperenhance-
ment + growth over 50% in 6 months), 5B: 2-5 cm lesion, 
5T: lesion with prior regional treatment, and 5X: > 5 cm 
lesion. There are some differences between OPTN and LI-
RADS. For example, OPTN includes all liver transplanta-
tion candidates, and LI-RADS has its eligibility criteria, 
e.g. concerning risk factors. OPTN recognises threshold 
growth as > 50% increase in size within < 6 months, while 
LI-RADS also accepts > 100% increase in size within 
> 6 months and a new observation > 10 mm.
The European Society of Gastrointestinal and Abdom-
inal Radiology (ESGAR) in 2016 issued its own guidelines 
on liver MR imaging including HCC diagnosis. There are 
no named categories, but diagnosis is also based on size 
(> 1 cm) and major features (arterial hyperenhancement 
and washout) as well as additional features: hepatobiliary 
phase hypointensity, T2-hyperintensity, and diffusion re-
Figure 13. Contrast enhanced computed tomography, arterial phase. 
The whole lesion is filled with lipiodol, no viable tissue visible
Figure 14. Magnetic resonance imaging, arterial phase. Viable tissue pre-
senting as hyperenhancing mass (white arrow) adjacent to post-TACE area 
(black arrow)
 CT/MRI LI-RADS v2017 – review of the guidelines
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striction, which is similar to LI-RADS. It does not give 
recommendations on management though.
The typical enhancement pattern is much more fre-
quent in larger HCCs than in smaller nodules: 24% in 
nodules < 1 cm, 28% in 1-2 cm nodules, and 47% in tu-
mours > 2 cm [13]. Smaller nodules, due to dual blood 
supply, are more often hypovascular. 
For lesions above 1 cm in diameter that do not show 
typical enhancement AASLD and EASL recommend bi-
opsy because imaging is not sufficient to make a definite 
diagnosis. For lesions under 1 cm in diameter recommen-
dations remain unchanged: follow-up at three months 
with the same technique that discovered the nodule. It is 
worth noting though that the prevalence of malignancy 
among 1-2 cm indeterminate nodules is low (14-23%), 
and biopsy of all such nodules results in many negative 
results [14]. For lesions < 1 cm the percentage of malig-
nant lesions is probably even smaller. 
According to LI-RADS, sub-centimetre lesions can be 
classified as LR-4 (probably HCC) at most. None of the 
classification systems is specific enough for lesions < 1 cm 
in diameter or for hypovascular lesions in HCC diagnosis. 
In such cases follow-up and biopsy, respectively, can be 
taken into consideration.
Conclusions
There is a need for language unification and thus improve-
ment of communication between specialists involved in 
HCC diagnosis and management, including hepatologists. 
There are many systems that attempt to address this prob-
lem, and each of them does it with a different approach. 
They are not flawless – they all lack specificity in sub-cen-
timetre and hypovascular lesions. 
LI-RADS is focused on maximising specificity for the 
diagnosis of HCC with few management suggestions, 
and as such it is a very useful tool in everyday practice. 
LI-RADS is frequently updated, very detailed, and con-
stantly evolving. The 2017 update emphasised its advan-
tages especially with the introduction of the treatment re-
sponse algorithm and clarification of many of its features. 
LI-RADS, with its granularity, high specificity of LR-5 
category, and frequent updates, seems the most thorough 
and useful classification system for HCC imaging. 
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